Sponsor Dossier
Accelagen
Sponsor Dossier for Accelagen. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABURA
- Brand: AETHOXYSKLEROL
- Brand: AMBRISENTAN MSN
- Brand: APOHIDE
- Brand: DEFERASIROX FCT MSN
- Brand: DIMETHYL
- Brand: ERLOTINIB ARX
- Brand: FEBUXOSTAT
About
Accelagen is an Australian Private Company with ABN 11142888766, registered in Victoria. The company is currently active.
Portfolio
Accelagen has 23 brands on the ARTG, of which 7 are indexable and 6 carry a Product Information document. 1 brand is PBS-listed, 1 has a PBAC outcome on record, and 1 has an AusPAR on record. Notable brands include ABURA, AETHOXYSKLEROL, AMBRISENTAN MSN, APOHIDE, DEFERASIROX FCT MSN, DIMETHYL, ERLOTINIB ARX, FEBUXOSTAT, FENOFIB, HARUROPI, LACOSAMIDE MSN, MOVANTIK.
Therapeutic focus
— Neurology: 4 brands — Immunology: 3 brands — Cardiology: 3 brands — Oncology: 3 brands — Other: 2 brands — Pain Management: 2 brands — Renal: 1 brand — Dermatology: 1 brand — Psychiatry: 1 brand — Haematology: 1 brand — Gastroenterology: 1 brand — Musculoskeletal: 1 brand
PBS footprint
1 brand is PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2013-07-01, across 1 brand with a PBAC outcome on record. The latest AusPAR is 2016-06-06, across 1 brand with an AusPAR on record.